Skip to main content

Table 1 Clinical features of study patients at the time of initial diagnosis and time of identification of refractoriness

From: PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

Clinical features Initial diagnosis refractoriness
Number (n = 28)/percentage (%) Number (n = 28)/percentage (%)
Fever 28/100.0 28/100.0
Neutrophils <1 × 109/L 15/53.6 13/46.4
Hgb <90 g/L 16/57.1 18/64.3
PLT <100 × 109/L 23/82.1 25/89.3
TG >3 mmol/L 17/60.7 18/64.3
Fgb <1.5 g/L 10/35.7 16/57.1
Ferritin ≥500 μg/L 21/75.0 25/89.3
ALT >40 U/L 24/85.7 24/85.7
TBiL >17.1 μmol/L 16/57.1 18/64.3
LDH >190 U/L 18/64.3 21/75.0
Splenomegaly 28/100.0 28/100.0
Hemophagocytosis 21/75.0 22/78.6
Decline of NK cell activity 17/60.7 18/64.3
Elevated soluble CD25 25/89.3 28/100.0
Positive EBV-DNA in whole blood 28/100.0 28/100.0
Positive EBER in lymph node/bone marrow 3/10.7 4/14.3
  1. Hgb hemoglobin, PLT platelet, Fgb fibrinogen, ALT alanine aminotransferase, TBiL total bilirubin, LDH lactic dehydrogenase